Relmada Therapeutics, Inc. logo

Relmada Therapeutics, Inc.

NASDAQ:RLMD

Overview | Financials
Company Name Relmada Therapeutics, Inc.
Symbol RLMD
Currency USD
Price 0.75
Market Cap 24,893,700
Dividend Yield 0%
52-week-range 0.24 - 4.47
Industry Biotechnology
Sector Healthcare
CEO Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
Website https://www.relmada.com

An error occurred while fetching data.

About Relmada Therapeutics, Inc.

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for

Related Stocks

PMV Pharmaceuticals, Inc. logo

PMV Pharmaceuticals, Inc.

PMVP

0.878 USD

Inogen, Inc. logo

Inogen, Inc.

INGN

6.425 USD

Rani Therapeutics Holdings, Inc. logo

Rani Therapeutics Holdings, Inc.

RANI

0.559 USD

Pharvaris N.V. logo

Pharvaris N.V.

PHVS

16.6 USD

Gossamer Bio, Inc. logo

Gossamer Bio, Inc.

GOSS

1.11 USD

Kiniksa Pharmaceuticals, Ltd. logo

Kiniksa Pharmaceuticals, Ltd.

KNSA

27.36 USD

Eagle Pharmaceuticals, Inc. logo

Eagle Pharmaceuticals, Inc.

EGRX

1.55 USD

Financials

Numbers are in millions USD

Numbers are in millions USD